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Recently, it has been suggested that metabolic syndrome should be considered a premorbid condition in younger individuals. We
evaluated the prevalence of metabolic syndrome in Estonia and compared the characteristic proﬁles between morbid metabolic
syndrome (previously established diabetes, hypertension, or dyslipidaemia) and premorbid metabolic syndrome subgroups. Our
study was a cross-sectional, population-based sample of the general population in Estonia aged 20–74 years (n = 495). Metabolic
syndrome was diagnosed by National Cholesterol Education Program Adult Treatment Panel III criteria. Insulin resistance was
estimated using the homeostasis model assessment (HOMA-IR). The crude and weighted prevalence of metabolic syndrome
was 27.9% and 25.9%, respectively. Despite being signiﬁcantly younger, the premorbid subgroup showed similar levels of insulin
resistance as the morbid subgroup (mean HOMA-IR ± SD 2.73 ± 1.8v e r s u s2 .97 ± 2.1, P = 0.5). The most important attribute
of metabolic syndrome is insulin resistance, which already characterises metabolic syndrome in the early stages of its metabolic
abnormalities.
1.Introduction
The metabolic syndrome (MS) has been characterized by a
clustering of multiple metabolic risk factors for cardiovascu-
lar disease and diabetes. Such factors include glucose intol-
erance, central obesity, hypertension, elevated triglycerides,
and/or low HDL-cholesterol. There is no generally accepted
pathophysiological model of MS, but insulin resistance has
been proposed as a central underlying mechanism [1].
Individuals aﬀected by MS have at least a ﬁvefold in-
creased risk of type 2 diabetes and a twofold increased risk of
cardiovascular disease [2, 3], the latter being independent of
classicalrisk factors, suchas high LDL-cholesteroland smok-
ing. Various diagnostic criteria of MS have been proposed by
diﬀerent organisations. Most recent deﬁnitions include the
National Cholesterol Education Program Adult Treatment
Panel III (NCEPATP III) criteria developedby the American
Heart Association/National Heart, Lung, and Blood Institute
[4] and the 2005 International Diabetes Foundation (IDF)
criteria [5]. In 2009, a Joint Interim Statement of several
international organisations agreed on the threshold values
of all the main components of MS (with the exception of
waist circumference) and declared that 3 out of 5 abnormal
ﬁndings would qualify an individual for MS [6].
MShasbecomeaworldwide epidemic,anditsprevalence
continues to rise. Among adults in the United States, the
prevalence of the ATP III-deﬁned MS increased from 23.7%
in years 1988–1992 to 34.6% in years 1999–2002 [7, 8].
While the prevalence of MS is lower in Northern and
Mediterranean Europe, it is increasing in many less devel-
oped nations [9]. Estonia is a small country in north-east of
Europe, whose population has undergone a rapid transition
towards a Western sedentary lifestyle over the last decades.
The prevalence of MS has not been previously studied in
Estonia.
MS may be present in a wide range of groups, from ap-
parently healthy younger individuals to older individuals
with advanced stages of cardiovascular disease. There is an
ongoing debate about the practical utility of MS [10–12].
Nevertheless, it has become widely accepted that it is a valu-
able tool for the early recognition of a high life-time risk of
diabetes and CVD [11, 13, 14].
The main aim of our population-based study was to as-
sess the prevalence of MS in Estonians aged 20–74 years.2 International Journal of Endocrinology
In addition, we identiﬁed a subgroup of apparently healthy
subjects (without previously established diabetes, hyperten-
sion, or dyslipidaemia) among all those with clinical MS,
and we explored the characteristic proﬁle of this subgroup
in comparison to the morbid MS subgroup.
2.Methods
Apopulation-basedcross-sectionalmulticentricstudyonthe
prevalence of metabolic disorders and associated risk factors
was conducted between November 2008 and May 2009 in
three diﬀerent counties of Estonia. The study population
consisted of randomly selected adults aged 20−74 years
from four general practitioner (GP) practices. The initial
study population was selected to be representative of the
general Estonian population in terms of age and gender. An
invitation letter about the study was sent to each participant.
The total response rate was 53.2% (42.3% in the youngest
age-group and 65.9% in those aged 45–74 years), resulting
in a total study population of 495 subjects, of which 214
were male and 281 female. This left a slight (<5%) under
representation of younger (20–39 years) age groups when
compared to the Estonian population.
On the day of the study, subjects were invited to their
GP surgery in the morning between 8a.m. and 11a.m. after
an overnight fast (lasting at least 10 hours). An informed
consent form was signed, and blood pressure, waist cir-
cumference, height, and weight were measured with the
participants wearing their indoor clothes without shoes.
Weight was measured to the nearest 0.1kg using a mechan-
ical scale. Height was measured to the nearest 0.5cm using
a stadiometer. Waist circumference was measured midway
between the lower rib margin and iliac crest. Blood pressure
wasmeasured using a mercury sphygmomanometer after the
patienthad been sitting forat least ﬁve minutes. The mean of
three consecutive measurements was used for analysis, with
at least a three-minute interval between each measurement.
Blood samples were taken to measure fasting glucose,
insulin, total cholesterol, HDL-cholesterol, and triglycerides.
For all nondiabetic subjects, the oral glucose tolerance test
was conducted by standard methodology (WHO 1999) with
Glycodyn solution (Bioﬁle Ltd, Turku, Finland). A face-to-
face clinical interview was conducted to assess other medical
conditions and cardiovascular risk factors.
Plasma glucosewas measured by the hexokinase method.
Total cholesterol, HDL cholesterol, and triglycerides were
measured using an enzymatic colorimetric assay (COBAS
INTEGRA 800 plus analyzer, Roche, Basel, Switzerland).
Plasma insulin was measured using a chemiluminescent
assay (Immulite 2000 analyzer, SiemensHealthcare Diagnos-
t i c s ,D e e r ﬁ e l d ,I L ,U S A ) .
Metabolic syndrome was diagnosed by having at least
three of the following NCEP ATP III criteria [4]: waist cir-
cumference ≥102cm in men and ≥88cm in women, blood
pressure ≥130/85mmHg or taking antihypertensive med-
ication, fasting glucose: ≥5.6mmol/L or previously diag-
nosed diabetes, triglycerides ≥1.7mmol/L or taking lipid-
regulating medication, high-density lipoprotein (HDL) cho-
lesterol <1.03mmol/L in men and <1.30mmol/L in women,
or drug treatment for reduced HDL cholesterol. For sub-
group analysis all subjects with MS were divided into two
groups: apparently healthy subjects without previously diag-
nosed diabetes, dyslipidaemia, or hypertension (premorbid
subgroup) and unhealthy subjectswith previousdiagnosis of
any of the aforementioned conditions (morbid subgroup).
Diabetes, impaired glucose tolerance, and impaired fasting
glucose were diagnosed according to WHO criteria [15].
Insulin resistance (IR) was estimated using the homeostasis
model assessment (HOMA) formula: HOMA-IR = fasting
glucose (mmol/L) × fasting insulin (mU/L)/22.5. IR was
deﬁnedastheupperquartileofHOMA-IRinthewholestudy
group (exempting subjects with previously known diabetes
mellitus), the threshold of which in whole study group
was found to be 1.92 (2.04 and 1.82 for men and women,
resp.). The subjects with previously diagnosed diabetes were
excluded from the calculation of the quartiles of HOMA-
IR for the potential impact of diabetes medication on
glucose and insulin values. In the subgroup of subjects with
previously diagnosed diabetes, the mean HOMA-IR (±SD)
was 3.85 ± 3.13.
The study was approved by the University of Tartu Ethics
Review Committee on Human Research.
2.1. Statistical Analysis. Due to the slight under representa-
tion of younger age-groups (20–39 years), the prevalence of
MS was weighted to the Estonian 20–74 year old population
(estimated in 2009). Descriptive analysis methods as means
and standard deviations were calculated for the continuous
variables. The Man-Whitney U-test was used for compar-
isons between diﬀerent subgroups. The prevalence of MS
was presented as a proportion with 95% conﬁdence intervals
(95%CI-s). The chi-square test(withBonferroni correction)
was used for multiple comparison of prevalence between
three age-groups. P values were considered statistically
signiﬁcant atthe0.05level.Statisticalanalysis was performed
using R software version 2.10.1.
3.Results
The prevalence of MS in our study of Estonian adults was
27.9%, 30.8% in men and 25.6% in women. The prevalence
of MS in our population, weighted for the average Estonian
population (estimated in 2009), was 25.9%, 29.4% in men
and 23.8% in women. The prevalence of MS increased
signiﬁcantly with age (Table 1). Prevalence was signiﬁcantly
(P-value = 0.02) higher in men when compared to women
in the youngest age-group only, and there were no gender-
speciﬁc diﬀerences in prevalence in the middle and older
age-groups (Table 1). Prevalence data on diabetes, impaired
glucose tolerance, and impaired fasting glucose in our study
population has been published elsewhere [16]. Most of
the subjects with MS had 3 components of the syndrome
(56.4%), 31.5% had 4, and 12.1% had all 5 components.
Arterial hypertension (93.6%), abdominal obesity (91.4%),
and impaired glucose metabolism (71.4%) were the most
common abnormalities in both sexes.
Anthropometric and biochemical characteristics of sub-
jects with and without MS are shown in Table 2.International Journal of Endocrinology 3
Table 1: Age- and gender-speciﬁc prevalence of metabolic syn-
drome in Estonia.
Age–group n % (95% CI)
20–44 years (n = 221) 42 19.0 (14.2–24.9)
Men (n = 105) 27 25.7 (17.9–35.3)
Women (n = 116) 15 12.9 (7.7–20.7)
45–60 years (n = 163) 46 28.2 (21.6–35.9)
Men (n = 64) 19 29.7 (19.2–42.6)
Women (n = 99) 27 27.3 (19.0–37.3)
61–74 years (n = 111) 50 45.0 (35.7–54.8)
Men (n = 45) 20 44.4 (30.0–59.9)
Women (n = 66) 30 45.5 (33.3–58.1)
Total (n = 495) 138 27.9 (24.0–32.1)
Men (n = 214) 66 30.8 (24.8–37.6)
Women (n = 281) 72 25.6 (20.7–31.2)






Age (years) 53.3 ± 13.94 4 .4 ±14.8
Waist (cm) 108.1 ± 11.98 7 .5 ±12.8
Men 110.1 ± 9.79 2 .4 ±11.3
Women 106.3 ± 13.48 4 .1 ±12.6
BMI (kg/m2)3 3 .3 ± 5.42 6 .2 ±5.2
Men 32.2 ± 4.62 6 .1 ±4.5
Women 34.4 ± 5.92 6 .2 ±5.6
HOMA-IR 2.88 ± 1.97 1.11 ±1.01
Men 3.02 ± 2.14 1.16 ±1.28
Women 2.75 ± 1.80 1.07 ±0.77
Systolic blood pressure
(mmHg) 141.4 ± 14.5 124.2 ±15.1
Diastolic blood pressure
(mmHg) 87.5 ± 8.57 8 .7 ±9.2
Cholesterol (mmol/L)∗ 5.88 ± 1.18 5.63 ±1.18
Triglycerides (mmol/L) 1.85 ± 0.89 1.10 ±0.51
HDL-cholesterol (mmol/L)
(men) 1.19 ± 0.36 1.48 ±0.42
HDL-cholesterol (mmol/L)
(women) 1.36 ± 0.36 1.74 ±0.43
Fasting glucose (mmol/L) 6.14 ± 1.08 5.16 ±0.46
2h glucose during OGTT
(mmol/L) 7.22 ± 2.79 5.11 ±1.81
Fasting insulin (mU/L) 10.44 ± 6.37 4.76 ±4.20
Impaired fasting glucose¤,$ 12 (9) 13 (4)
Impaired glucosetolerance¤ 27 (20) 17 (5)
Diabetes¤ 33 (24) 6 (2)
Data presented as mean ± SD, ¤data presented as n (%), P<0.0001, $P =
0.04, ∗P = 0.03.
OGTT: oral glucose tolerance test.
We also compared pre-morbid subjects with MS against
morbid subjects with MS in our subgroup analysis. The pre-
morbid subgroup was signiﬁcantly younger and had lower
systolic blood-pressure, lower BMI, and smaller waist cir-
cumference (for BMI and waist, only the diﬀerence between
pre-morbid and morbid men reached statistical signiﬁ-
cance). HOMA-IR values and lipid levels did not diﬀer be-
tween morbid and pre-morbid subgroups (Table 3).
Al a r g ed i ﬀerence was observed in the insulin resistance
between subjects with MS and without MS: the prevalence
of insulin resistance (deﬁned as the top quartile of HOMA-
IR in whole study group excluding subjects with previously
known diabetes) among subjects with and without MS was
62.3% (95% CI 53.6–70.3) and 12.4% (95% CI 9.2–16.4),
respectively. The prevalence of insulin resistance among
subjects with MS in the pre-morbid and morbid subgroups
did not diﬀer, being 58.8% (95% CI 44.2–72.1%) and 64.4%
(95% CI 53.3–74.1%), respectively (P-value 0.64).
4.Discussion
In this population-based cross-sectional study, we estimated
the age- and gender-speciﬁc prevalence of MS for 20–74-
year-old Estonian adults according to NCEP ATP III criteria.
A recent joint scientiﬁc statement by diﬀerent international
organisations agreed on the threshold values for most
of the components of MS, with the exception of waist
circumference for abdominal obesity. The IDF criteria deﬁne
abdominal obesity at a lower threshold (≥94cm in men
and ≥80cm in women) than the NCEP ATP III criteria [6].
We chose to use the NCEP ATP III criteria for prevalence
estimations, since higher thresholds of waist circumference
aregenerallyusedinEuropeandUnitedStates[6].Moreover,
a recent meta-analysis of nearly one million patients con-
vincingly demonstrated a 2-fold increase in cardiovascular
outcomes and a 1.5-fold increase in all-cause mortality in
individuals diagnosed with MS according to the NCEP ATP
III criteria [3], giving further credibility to the practical
usefulness of NCEP ATP III criteria.
We believe that our study population is truly representa-
tive for the general Estonian population (1.34 million inhab-
itants in 2009). The sample of 495 subjects represented a
mixed urban-rural population of Estonia and it was ran-
domly drawn from the patient registers of four general
practice centres. It is important to note that every resident
of Estonia is automatically added to a general practitioner
register according to their address. In our study, we found
27.9% of subjects to be aﬀected by MS and the weighted
prevalence rate of the general population to be 25.9%. How-
ever, the low response rate, especially in the youngest age
group, may have biased our results because the proportion
of healthy subjects may have been higher among those who
did not respond. In comparison with the prevalence of MS
in other countries, the DECODE study including pooled
data from nine European population-based cohorts showed
higher average prevalence of MS: 32.2% and 28.5% for
men and women, respectively [17]. However, the DECODE
study population was notably older (30–89 years). More4 International Journal of Endocrinology
Table 3: Comparisonof premorbid1 and morbid2 subgroup in subjects with metabolic syndrome.
Characteristics Premorbid MS subgroup
n = 51
Morbid MS subgroup
n = 87 P value
Age (years) 45.86 ±14.65 7 .72 ±11.3 <0.0001
Waist (cm) 105.3 ±12.7 109.7 ±11.10 . 0 2
Men 106.6 ±9.9 112.8± 8.8 0.008
Women 103.7 ±15.8 107.5 ±12.10 . 1 9
BMI (kg/m2)3 2 .2 ±6.13 4 .0 ±25.10 . 0 3
Men 30.8 ±4.63 3 .2 ±4.4 0.0495
Women 34.1 ±7.43 4 .6 ±32.70 . 4 7
HOMA-IR 2.73 ±1.82 .97 ±2.10 . 5 0
Men 2.87 ±1.93 .14 ±2.30 . 6 5
Women 2.54 ±1.72 .84 ±1.80 . 5 1
Systolic blood pressure (mmHg) 137.1 ±14.0 143.9 ±14.2 0.007
Diastolic blood pressure (mmHg) 87.2 ±8.48 7 .7 ±8.70 . 7 2
Cholesterol (mmol/L) 6.0 ±1.45 .8 ±1.10 . 8 5
Triglycerides (mmol/L) 2.03 ±1.04 1.75 ±0.77 0.22
HDL-cholesterol (mmol/L)(men) 1.15 ±0.31 1.22 ±0.40 0.46
HDL-cholesterol (mmol/L)(women) 1.26 ±0.26 1.40 ±0.40 0.14
Fasting glucose (mmol/L) 5.8 ±0.76 .3 ±1.20 . 0 2
2h glucose during OGTT (mmol/L) 6.5 ±2.27 .7 ±3.10 . 0 3
Fasting insulin (mU/L) 10.5 ±6.51 0 .4 ±6.30 . 9 6
Impaired fasting glucose¤ 6 (12) 6 (7) 0.4
Impaired glucose tolerance¤ 9 (18) 18 (21) 0.8
Diabetes¤ 5 (10) 28 (32) 0.006
Data presented as mean ± SD; ¤data presented as n (%); OGTT: oral glucose tolerance test; Subjects without1or with2 previously diagnosed and/or treated
diabetes, dyslipidaemia,and hypertension.
recent studies from Europe that have estimated prevalence
according to NCEP ATP III in age groups comparable to
that of our study population have shown comparable results:
25.9% in Norway [18], 28.8% in Turkey [19], and 24.7%
in Luxembourg [20]. Furthermore, our estimates of the
prevalenceofdiabetes(7.0%)andimpairedglucosetolerance
(8.0%) in Estonia are also in comparable to those of other
developed countries [16]. Thus, the prevalence of metabolic
disorders in Estonia—a former socialist country undergoing
arapidtransition totheWesternsedentarylifestyle—appears
to be similar to the rest of the developed world.
M Sw a sm o r ec o m m o ni nm e nt h a nw o m e ni nt h e
younger age group only, followed by an equalisation of the
gender-speciﬁc prevalence in the middle age group and
thereafter. These gender-speciﬁc diﬀerences in Estonia are
generally comparable to the patterns described in other pop-
ulations [21]. However, the diﬀerence in prevalence between
the men (25.7%) and women (12.9%) in our youngest age
group is more pronounced when compared to data, for
example,fromtheUSA[21].Ourneighbouringcountry Fin-
land recently reported a similar 2-fold increase in the preva-
lence of MS among 24–39-year-old men, when compared
to women [22]. These regional observations are particularly
noteworthy given that of all the countries of the European
Union, gender diﬀerences in life expectancy are also the
greatest in the Baltic States [23]. Our ﬁndings suggest that
the distribution of MS between young men and women
may be partly responsible for the large diﬀerences in life
expectancy in the North-East of Europe, as the life expectan-
cy of such young men may be reduced by subsequentcardio-
vasculardisease anddiabetes.Futurestudiescoulddetermine
whether young men with MS are so prevalent in North-
East of Europe, due to genetic vulnerability, environmental
inﬂuence, or an interaction between these two.
The practical utility of MS has been greatly challenged
during the recent years [10, 11, 24, 25]. The following con-
cerns have been raised by critics of the concept: no unifying
pathophysiological mechanism of MS has been identiﬁed
as yet; the risk of cardiovascular disease conferred by the
syndrome appears no greater than the sum of its parts; the
rationale for the thresholds of various diagnostic criteria
is still poorly deﬁned [24]. Another shortcoming has been
the inclusion of individuals with established diabetes and
heart disease [11]. However, it is still widely recognised that
beyond age, high LDL-cholesterol, and other standard risk
factors, MS helps to identify residual vascular risk associ-
ated with insulin resistance and atherogenic dyslipidaemia
(low HDL-cholesterol, high triglycerides, small dense LDL-
cholesterol) [12, 14]. There is a general agreement that MS
denotes a high life-time risk of diabetes and cardiovascular
disease and it has been proposed that after exclusion of indi-
viduals with established diabetes and cardiovascular diseaseInternational Journal of Endocrinology 5
MS should be considered a pre-morbid condition [11]. This
prompted us to ask whether in our study population the
individuals, who fulﬁlled the criteria of MS, but had not
been previously diagnosed with diabetes, hypertension,
and/or dyslipidaemia (high triglycerides and/or low HDL-
cholesterol), represented a typical subgroup of subjects with
MS as compared with individuals with established car-
diometabolicabnormalities. In particular, we were interested
whether in the pre-morbid subgroup MS was characterised
by insulin resistance. As expected, pre-morbid individuals
were signiﬁcantly younger than morbid subjects, and male
subjects were signiﬁcantly less obese (by both waist cir-
cumference and BMI). Despite these diﬀerences, pre-morbid
subjects proved to be as insulin resistant as morbid subjects
estimated both by the mean HOMA-IR and by proportion
of the subjects with HOMA-IR in the upper quartile of
HOMA-IR in the whole study group. This may indicate that
insulin resistance is a hallmark of MS already in the early
stage of this disorder. However, insulin resistance of the
same magnitude in the premorbid and morbid subgroups
with MS should be interpreted with caution, due to the
therapeutic eﬀects of lifestyle and medical interventions
on alleviating insulin resistance, in the morbid subgroup.
Elevations of insulin concentration have been shown to
precede the development of diabetes and multiple metabolic
disorders in large prospective studies [26, 27]. Moreover,
insulin resistance per se is a well-established independent
predictor of cardiovascular disease [28, 29]. In line with
previous studies [30, 31], our results support the conclusion
that a high proportion of insulin resistant subjects, both
apparently healthy individuals and those with established
cardiometabolic abnormalities, can be identiﬁed by simple
measurements deﬁning MS. Therefore, MS seems to remain
a useful practical tool for early identiﬁcation of apparently
healthy individuals at a considerable risk of cardiovascular
disease and diabetes.
5.Conclusions
The prevalence of metabolic syndrome (as deﬁned by NCEP
ATP III) in Estonia was comparable to other European
countries. However, it appears that younger men in Estonia
have a relatively high prevalence of MS. Insulin resistance
already characterised MS in apparently healthy individuals
without previously diagnosed comorbidities. This suggests
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